文献速递神经免疫

血清α-亚麻酸与多发性硬化长期活动及进展的关联

Serum Alpha-Linolenic Acid and Long-Term Multiple Sclerosis Activity and Progression.
PubMed 文献 · Neurology · 2025-07-17

基于BENEFIT临床试验468例(278例随访至11年)的前瞻性研究,用气相色谱测血清脂肪酸。基线血清ALA最高四分位较低四分位者,5年和11年临床确诊MS风险及复发风险均更低(HR/RR约0.60-0.65),且5年残疾进展更慢;其他35种脂肪酸无此关联。

要点

  • 基线血清ALA较高与5年和11年临床确诊MS风险降低相关。
  • 基线血清ALA较高与5年和11年复发风险降低相关。
  • 基线ALA较高与5年MSFC残疾下降更慢相关,11年未达统计学显著。

核心结论

  • 较高血清ALA水平与临床确诊MS、复发和残疾进展风险降低相关,其他脂肪酸结果阴性或不一致。

研究设计与样本

  • 前瞻性研究,纳入BENEFIT临床试验参与者,从随机化起采集血清,用气相色谱测脂肪酸。
  • 随访468例5年,其中278例随访至11年;基线中位年龄30岁,女性占71%。

主要发现

  • 基线血清ALA最高vs最低四分位,5年和11年临床确诊MS的多变量校正HR分别为0.60(95%CI 0.39-0.95)和0.60(95%CI 0.37-0.98)。
  • 基线血清ALA最高vs最低四分位,5年和11年复发的多变量校正RR分别为0.60(95%CI 0.38-0.94)和0.65(95%CI 0.43-0.99)。
  • 其他35种脂肪酸均与临床确诊MS风险无关;3种脂肪酸与5年复发率相关但与11年无关。
  • 较高ALA水平与5年MSFC残疾下降更慢相关,11年结果相似但未保持统计学显著性。
  • 基线ALA水平与认知功能变化、确认的EDSS进展时间、新活动性病灶或脑体积丢失无关。

临床怎么用

  • 血清ALA水平或可作为MS疾病活动与进展风险的辅助生物标志物,但尚不能据此推荐补充ALA。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND AND OBJECTIVES: Higher dietary intake of alpha-linolenic acid (ALA), a plant-derived omega-3 polyunsaturated fatty acid (PUFA), was associated with a lower risk of multiple sclerosis (MS) in a prospective cohort study and lower risk of new lesions, relapses, and disability progression in a patient cohort. We examined whether serum levels of ALA and other PUFAs predicted MS outcomes up to 11 years after clinical onset. METHODS: This prospective study was conducted among participants in the BENEFIT clinical trial, who had serum samples collected starting at randomization. Serum fatty acids were measured using gas chromatography. We evaluated the association of individual fatty acids with time to clinically definite MS (CDMS) and other measures of disease activity and progression using Cox, negative binomial, and linear regression. RESULTS: We followed 468 participants for 5 years, including 278 followed to year 11. At baseline, the median age was 30 years and 71% were women. Higher baseline serum ALA levels were associated with a lower risk of CDMS and relapses during follow-up. The multivariable-adjusted hazard ratios for CDMS comparing top to bottom quartile were 0.60 (95% CI 0.39-0.95) and 0.60 (95% CI 0.37-0.98) after 5 and 11 years, respectively. The multivariable adjusted risk ratios for relapses comparing top to bottom quartile were 0.60 (95% CI 0.38-0.94) and 0.65 (95% CI 0.43-0.99) after 5 and 11 years, respectively. None of the other 35 fatty acids were associated with CDMS risk. Three fatty acids were associated with relapse rate after 5 years, but not 11 years. Higher ALA levels were associated with a slower decline in MS Functional Composite, an assessment of disability, at 5 years. The association was similar at 11 years, but the results did not retain statistical significance. Baseline ALA levels were not associated with subsequent changes in cognitive function, time to confirmed Expanded Disability Status Scale progression, new active lesions, or brain volume loss. DISCUSSSION: Higher serum ALA levels were associated with a lower risk of CDMS, relapses, and disability progression in a large prospective cohort. The results were null or inconsistent for other fatty acids.

来源:Neurology,查看原文。版权归原作者所有。

引用

  1. Cortese M, Peng X, Edan G, et al. Serum Alpha-Linolenic Acid and Long-Term Multiple Sclerosis Activity and Progression. Neurology. 2025. PMID: 40674673. doi:10.1212/WNL.0000000000213905

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。